Related Experiment Video

Updated: May 17, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

NLK is a novel therapeutic target for PTEN deficient tumour cells

Ana M Mendes-Pereira1, Christopher J Lord, Alan Ashworth

  • 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

Plos One
|November 13, 2012
PubMed

Insights

Inhibiting Nemo-Like Kinase (NLK) is synthetically lethal with PTEN deficiency in cancer cells. This discovery offers a new therapeutic strategy targeting tumors with PTEN loss, potentially inducing cancer cell senescence.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • PTEN (Phosphatase and tensin homolog) is a tumor suppressor gene frequently altered in human cancers.
  • Loss of PTEN function presents a therapeutic vulnerability that can be exploited through synthetic lethality (SL).

Purpose of the Study:

  • To identify therapeutic targets that exhibit synthetic lethality with PTEN deficiency.
  • To investigate the role of Nemo-Like Kinase (NLK) in PTEN-deficient cancer cells.

Main Methods:

  • Utilized isogenic models of PTEN deficiency.
  • Conducted high-throughput RNA interference (RNAi) screening to identify SL interactions.
  • Investigated the role of FOXO1 (Forkhead box O1) in mediating the observed SL.

Main Results:

  • Identified NLK inhibition as synthetically lethal with PTEN deficiency.
  • Demonstrated that the SL effect is mediated by the transcription factor FOXO1.
  • Observed that PTEN-deficient cells treated with NLK inhibition undergo senescence, halting proliferation.

Conclusions:

  • NLK inhibition represents a promising synthetic lethal strategy for treating cancers with PTEN deficiency.
  • Targeting NLK may be a viable approach to induce senescence and inhibit tumor growth in PTEN-deficient malignancies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...